[bDMARDs/JAKiのスイッチングを必要とするリウマチ性関節炎患者の無効治療の予測要因:単一センター前向き研究からのデータ]
A O Bobkova1, A M Lila1,2, A E Karateev1
1Nasonova Research Institute of Rheumatology.
Terapevticheskii arkhiv
|February 18, 2026
まとめ
リウマチ性関節炎 (RA) の場合,生物学的病変変性抗レウマティック薬 (bDMARDs) またはジャヌスキナーゼ阻害剤 (JAKi) を切り替えることは,しばしば効果的ではありません. 高いBMI,痛み,および心理的要因は,これらのRA治療に対する反応が悪いことを予測します.
科学分野:
- レウマトロジーの病理学
- 免疫学 免疫学とは
- 薬理学 薬理学とは
背景:
- リウマチ性関節炎 (RA) の治療目標は,bDMARDsやJAKiのような先進的な治療法であっても,しばしば達成されない.
- 治療が失敗すると,代替のbDMARDsまたはJAKiに切り替えることが必要になりますが,成功の予測要因は不明です.
研究 の 目的:
- 以前の無効性のためにbDMARDs/JAKiを切り替えるRA患者における治療反応の低下に関連した要因を特定する.
- RAにおいてbDMARDs/JAKiを交換した後の治療結果の予測モデルを開発する.
主な方法:
- bDMARD/JAKiの失敗を前にした164人のRA患者を分析した.
- 疾患活動スコア (DAS28-CRP) は,スイッチアップの6ヶ月後に評価されました.
- バイナリロジスティック回帰は,不良応答の予測要因を特定するために使用されました.
主要な成果:
- 48.8%の患者が不良な反応を示した (DAS28-CRP > 3.2).
- 反応の不良を予測する要因には,より高いBMI,RA発症年齢,関節数の増加,痛みの悪化,心理的苦痛などがある.
- BMI,RFセロネガティブ性,中央感知インベントリー (CSI),神経疾患の痛み,およびグルココルチコイド (GC) の使用を組み込んだ予測モデルは,77.5%の感受性と70.2%の特異性を達成しました.
結論:
- ベースラインより高いRA活動,痛みの重度,BMI,中央の感受性,および精神情緒的障害は,bDMARDs/JAKiを切り替えるときに悪い結果を予測します.
- ベースラインでのグルココルチコイドの使用は,治療のスイッチへの負の反応とも関連しています.
- これらの発見は,RAの治療戦略をパーソナライズするのに役立ちます.
関連する概念動画
01:29Therapeutic Drug Monitoring: Affecting Factors
258
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
258
01:21Rheumatic Heart Disease III: Medical Management
393
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
393
01:29Inflammatory Bowel Disease IV: Pharmacological Management
817
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
817
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
607
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
607
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
574
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
574
01:20The JAK-STAT Signaling Pathway
13.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.2K